Literature DB >> 35880971

A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate using ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry and liquid chromatography-solid-phase extraction-nuclear magnetic resonance.

Donghai Xu1,2, Fangfang Pan1, Hao Ruan1,2, Nan Sun2.   

Abstract

RATIONALE: Hydroxychloroquine sulfate is effective in the treatment of malaria and autoimmune diseases and as an antiviral drug. However, unreported impurities are often detected in this drug, which pose a health risk. In this study, the structures of hydroxychloroquine and six unknown impurities were analyzed using ultra-high-performance liquid chromatography-quadrupole/time-of-flight-tandem mass spectrometry (UHPLC-Q/TOF/MS/MS), and the structures were characterized using liquid chromatography-solid-phase extraction-nuclear magnetic resonance (LC-SPE-NMR) spectroscopy.
METHODS: An Agilent InfinityLad Poroshell HPH-C18 column (100 × 4.6 mm, 2.7 μm) was used. For the analysis of hydroxychloroquine and six unknown impurities, the mobile phase was 20 mM ammonium formate aqueous solution and methanol/acetonitrile (80:20, v/v) using gradient elution. Full-scan MS and MS2 were performed to obtain as much structural information as possible. In addition, six unknown impurities were separated by semi-preparative liquid chromatography and characterized using LC-SPE-NMR.
RESULTS: The MS2 fragmentation patterns of the impurities were investigated, leading to more structural information and an understanding of the fragmentation pathways of the impurities. The structures of the unknown impurities were confirmed using NMR. In addition, some possible pathways of the formation of the impurities in the drugs were outlined, and these impurities were found to be process impurities.
CONCLUSIONS: Based on the identification and characterization of these impurities, this study also describes the cause of the production of the impurities and provides insights for companies to improve their production processes and a scientific basis for the improvement of the related pharmacopoeias.
© 2022 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35880971      PMCID: PMC9350102          DOI: 10.1002/rcm.9358

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.586


  25 in total

1.  Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies.

Authors:  Yashpal S Chhonker; Richard L Sleightholm; Jing Li; David Oupický; Daryl J Murry
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-11-23       Impact factor: 3.205

2.  Characterization of four new photodegradation products of hydroxychloroquine through LC-PDA, ESI-MSn and LC-MS-TOF studies.

Authors:  Balraj Saini; Gulshan Bansal
Journal:  J Pharm Biomed Anal       Date:  2013-06-21       Impact factor: 3.935

3.  One step derivatization and dispersive liquid-liquid microextraction of hydroxychloroquine sulfate for its sensitive and accurate determination using GC-MS.

Authors:  Süleyman Bodur; Sezin Erarpat; Ömer Tahir Günkara; Sezgin Bakırdere
Journal:  J Pharmacol Toxicol Methods       Date:  2021-10-22       Impact factor: 1.950

4.  Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate.

Authors:  E W McChesney
Journal:  Am J Med       Date:  1983-07-18       Impact factor: 4.965

5.  Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?

Authors:  Christopher Wright; Carly Ross; Niall Mc Goldrick
Journal:  Evid Based Dent       Date:  2020-06

6.  Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Marion Mafham; Louise Linsell; Jennifer L Bell; Natalie Staplin; Jonathan R Emberson; Martin Wiselka; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Tony Whitehouse; Timothy Felton; John Williams; Jakki Faccenda; Jonathan Underwood; J Kenneth Baillie; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Wei Shen Lim; Alan Montgomery; Kathryn Rowan; Joel Tarning; James A Watson; Nicholas J White; Edmund Juszczak; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

7.  Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study.

Authors:  Ozgur Sogut; Mehmet Mustafa Can; Ramazan Guven; Onur Kaplan; Hüseyin Ergenc; Tuba Betül Umit; Olgun Demir; Murat Kaya; Tarık Akdemir; Sümeyye Cakmak
Journal:  Am J Emerg Med       Date:  2020-12-11       Impact factor: 2.469

8.  Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial.

Authors:  Raymond Chee Seong Seet; Amy May Lin Quek; Delicia Shu Qin Ooi; Sharmila Sengupta; Satish Ramapatna Lakshminarasappa; Chieh Yang Koo; Jimmy Bok Yan So; Boon Cher Goh; Kwok Seng Loh; Dale Fisher; Hock Luen Teoh; Jie Sun; Alex R Cook; Paul Anantharajah Tambyah; Mikael Hartman
Journal:  Int J Infect Dis       Date:  2021-04-14       Impact factor: 3.623

9.  Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations.

Authors:  Olfa Noureddine; Noureddine Issaoui; Mouna Medimagh; Omar Al-Dossary; Houda Marouani
Journal:  J King Saud Univ Sci       Date:  2021-01-06

10.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Authors:  Christian A Devaux; Jean-Marc Rolain; Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-12       Impact factor: 5.283

View more
  1 in total

1.  A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate using ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry and liquid chromatography-solid-phase extraction-nuclear magnetic resonance.

Authors:  Donghai Xu; Fangfang Pan; Hao Ruan; Nan Sun
Journal:  Rapid Commun Mass Spectrom       Date:  2022-10-30       Impact factor: 2.586

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.